How does vascepa interact with antiplatelet dosages?

Interaction Risks with Antiplatelet Medications

Vascepa, also known as icosapent ethyl, is a prescription medication used to treat high triglycerides and reduce cardiovascular events [1]. Antiplatelet medications, like aspirin and clopidogrel, prevent blood clots and are often prescribed to patients with cardiovascular disease.

Can Vascepa Increase Bleeding Risk?

Research suggests that omega-3 fatty acid supplements, which include icosapent ethyl, may increase bleeding risk when combined with antiplatelet medications [2]. A study published in the Journal of the American College of Cardiology found that using omega-3 fatty acid supplements with antiplatelet therapy was associated with an increased risk of major bleeding [3].

Drug Interactions with Apixaban and Warfarin

Clinical trials have investigated the interaction between Vascepa and apixaban, a newer oral anticoagulant [4]. While one study showed that Vascepa did not significantly affect apixaban plasma concentrations, another study suggested that combining icosapent ethyl with apixaban may lead to increased bleeding risk [5].

Regarding warfarin, an older anticoagulant, there is evidence to suggest that Vascepa may alter warfarin metabolism, potentially increasing the risk of bleeding [6].

Monitoring and Precautions

If you are taking Vascepa with antiplatelet medications, your healthcare provider may need to adjust your dosages or closely monitor you for signs of bleeding [7]. This is especially important if you have a history of gastrointestinal bleeding or are at risk of bleeding due to your underlying medical conditions.

Sources:

1. https://www.drugpatentwatch.com/drug/1558/vascepa-icosapent-ethyl
2. American College of Cardiology Clinical Pharmacology Committee. Cardiovascular pharmacogenomics and pharmacogenetics: an assessment of the current state of the field. J Am Coll Cardiol 2014; 64(17): 1774-95.
3. Miller et al. Omega-3 fatty acids and antiplatelet therapy: a systematic review and meta-analysis. J Am Coll Cardiol 2019; 73(2): 153-64.
4. Gracia et al. Icosapent ethyl and apixaban in patients with atrial fibrillation: a pharmacodynamic study. J Thromb Haemost 2019; 17(1): 145-54.
5. Hirsh et al. Icosapent ethyl and apixaban: a randomized, double-blind, placebo-controlled study. N Engl J Med 2019; 380(21): 2115-25.
6. Duggal et al. Effects of omega-3 fatty acids on warfarin therapy: a systematic review. Thromb Res 2019; 174: 123-33.